Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.
Loading...
Embargo End Date
ICR Authors
Authors
Houda, I
Dickhoff, C
Uyl-de Groot, CA
Damhuis, RAM
Reguart, N
Provencio, M
Levy, A
Dziadziuszko, R
Pompili, C
Di Maio, M
Thomas, M
Brunelli, A
Popat, S
Senan, S
Bahce, I
Dickhoff, C
Uyl-de Groot, CA
Damhuis, RAM
Reguart, N
Provencio, M
Levy, A
Dziadziuszko, R
Pompili, C
Di Maio, M
Thomas, M
Brunelli, A
Popat, S
Senan, S
Bahce, I
Document Type
Journal Article
Date
2024-03-01
Date Accepted
2024-01-08
Abstract
The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, and neoadjuvant nivolumab combined with chemotherapy, and the approval of other agents or new indications may follow soon. Despite encouraging results, many unaddressed questions remain. Moreover, the transformed treatment paradigm in resectable NSCLC can pose major challenges to healthcare systems and magnify existing disparities in care as differences in reimbursement may vary across different European countries. This Viewpoint discusses the challenges and controversies in resectable early-stage NSCLC and how existing inequalities in access to these treatments could be addressed.
Citation
The Lancet Regional Health - Europe, 2024, 38 pp. 100841 -
Source Title
The Lancet Regional Health - Europe
Publisher
ELSEVIER
ISSN
2666-7762
eISSN
2666-7762
2666-7762
2666-7762